| Biologic Therapy |
1 |
1 |
| CAR-T |
0 |
0.98 |
| Systemic Lupus Erythematosus |
0 |
0.64 |
| Rheumatic Disease |
0 |
0.99 |
| Remission |
0 |
0.25 |
| Refractory |
0 |
0.18 |
| Autoimmune Disease |
0 |
0.14 |
| Healthcare and Medical Technology |
0 |
0.14 |
| Lupus Nephritis |
0 |
0.14 |
| Clinical Research |
0 |
0.11 |
| Lupus |
0 |
0.11 |
| Neurotoxicity |
0 |
0.11 |
| Stem Cell Research and Therapy |
0 |
0.1 |
| Toxicology |
0 |
0.1 |
| Patient Safety |
0 |
0.08 |
| Adverse Effects |
0 |
0.07 |
| Antigens |
0 |
0.07 |
| Europe |
0 |
0.07 |
| Immunoglobulin A (IgA) |
0 |
0.07 |
| Immunology |
0 |
0.07 |
| Nephritis |
0 |
0.07 |
| New York |
0 |
0.07 |
| Receptors |
0 |
0.07 |
| Scleroderma |
0 |
0.07 |
| End-Stage Liver Disease |
0 |
0.06 |